LN
Leslie V Norwalk
Director

Leslie V Norwalk insider trades: Neurocrine Biosciences (NBIX) stock sales

Director, Neurocrine Biosciences Last trade Jul 28, 2026 80 Form 4 filings
$2.3M
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2024
12
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Leslie reports to the SEC

and 6 more companies

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 28, 2026NBIX↓ Sell$228K
May 12, 2026NBIX↓ Sell$591K
Jan 8, 2026GMED↓ Sell$202K
Dec 16, 2025NBIX↓ Sell$946K
Dec 12, 2025GMED↓ Sell$355K
Jul 11, 2024GMED↓ Sell$70K
May 17, 2024NBIX↓ Sell$157K
Mar 15, 2024GMED↓ Sell$551K
Feb 27, 2024NBIX↓ Sell$1.1M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other NBIX insiders

Open-market trades in the last 12 months

About Leslie V Norwalk's insider trades

Leslie V Norwalk is a director at Neurocrine Biosciences (NBIX). Since Feb 27, 2024, Leslie has reported no open-market purchases and 9 sales worth $4.2M on SEC Form 4. In the last 12 months: 5 sales ($2.3M).

Their filings also include grants and awards (60 filings), option exercises (12 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.